EPI-001 is a compound that has been studied for its potential therapeutic applications, particularly in the field of oncology. It functions as an androgen receptor antagonist, which makes it a candidate for treating prostate cancer. By inhibiting the androgen receptor, EPI-001 can potentially block the growth and proliferation of cancer cells that rely on androgen signaling for their survival. This mechanism is especially relevant in castration-resistant prostate cancer, where traditional hormone therapies are no longer effective. Research is ongoing to explore its efficacy and safety in clinical settings, with the hope of developing it into a viable treatment option for patients with advanced prostate cancer.